Ubiquilin 2 enhances osteosarcoma progression through resistance to hypoxic stress

Tsukamoto,Shinji; Shimada,Keiji; Honoki,Kanya; Kido,Akira; Akahane,Manabu; Tanaka,Yasuhito; Konishi,Noboru

doi:10.3892/or.2015.3788

Ubiquilin 2 enhances osteosarcoma progression through resistance to hypoxic stress

Authors:
- Shinji Tsukamoto
- Keiji Shimada
- Kanya Honoki
- Akira Kido
- Manabu Akahane
- Yasuhito Tanaka
- Noboru Konishi
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Nara 634-8521, Japan, Department of Pathology, Nara Medical University, Kashihara, Nara 634-8521, Japan, Department of Public Health, Health Management and Policy, Nara Medical University, Kashihara, Nara 634-8521, Japan
Published online on: February 9, 2015 https://doi.org/10.3892/or.2015.3788
Pages: 1799-1806

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ubiquilin 2 (UBQLN2), a member of the ubiquitin-like protein family (ubiquilins), maintains protein homeostasis. Although UBQLN2 has been implicated in the pathogenesis of neurodegenerative diseases, it is also associated with malignant tumors. Therefore, we examined whether UBQLN2 plays a role in human osteosarcoma. The human osteosarcoma cell line MG63 was transfected with UBQLN2 siRNA and cultured under hypoxic conditions. The rat osteosarcoma cell line COS1NR was inoculated into Fischer 344 rats, followed by injection of UBQLN2 siRNA with atelocollagen. An immunohistochemical analysis of UBQLN2 was performed using 34 cases of human high-grade osteosarcomas, and metastasis-free survival was estimated by the Kaplan-Meier method. Silencing of UBQLN2 by siRNA transfection under hypoxia led to activation of JNK and p38, resulting in induction of apoptosis in the osteosarcoma cell line MG63. Injection of UBQLN2 siRNA suppressed tumor growth in the rat osteosarcoma model, followed by apoptosis induction. The immunohistochemical examination revealed that high UBQLN2 expression was significantly associated with the unfavorable metastasis-free survival of osteosarcoma patients. UBQLN2 plays an important role in resistance to hypoxic stress and enhances tumor progression in osteosarcoma. UBQLN2 may be a new molecular target for chemotherapeutics and a useful clinicopathological marker in human osteosarcoma.

View Figures

View References

1	Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
2	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-N-allyl-amino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res. 13:1783–1788. 2007. View Article : Google Scholar : PubMed/NCBI
4	Ebb D, Meyers P, Grier H, et al: Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children’s Oncology Group. J Clin Oncol. 30:2545–2551. 2012. View Article : Google Scholar : PubMed/NCBI
5	Weigel B, Malempati S, Reid JM, et al: Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 61:452–456. 2014. View Article : Google Scholar
6	Moroney J, Fu S, Moulder S, et al: Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 18:5796–5805. 2012. View Article : Google Scholar : PubMed/NCBI
7	Bertram L, Hiltunen M, Parkinson M, et al: Family-based association between Alzheimer’s disease and variants in UBQLN1. N Engl J Med. 352:884–894. 2005. View Article : Google Scholar : PubMed/NCBI
8	Deng HX, Chen W, Hong ST, et al: Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 477:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
9	Beverly LJ, Lockwood WW, Shah PP, Erdjument-Bromage H and Varmus H: Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci USA. 109:E119–E126. 2012. View Article : Google Scholar : PubMed/NCBI
10	Honoki K, Mori T, Tsutsumi M, et al: Heterogeneous pattern of gene expression in cloned cell lines established from a rat transplantable osteosarcoma lung metastatic nodule. Cancer Lett. 127:221–228. 1998. View Article : Google Scholar : PubMed/NCBI
11	Honoki K, Tsutsumi M, Miyauchi Y, et al: Increased expression of nucleoside diphosphate kinase/nm23 and c-Ha-ras mRNA is associated with spontaneous lung metastasis in rat-transplantable osteosarcomas. Cancer Res. 53:5038–5042. 1993.PubMed/NCBI
12	Luu HH, Kang Q, Park JK, et al: An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 22:319–329. 2005. View Article : Google Scholar : PubMed/NCBI
13	Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F: Osteogenic tumours. WHO Classification of Tumours of Soft Tissue and Bone. IARC; Lyon: pp. 275–296. 2013
14	Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. The American Joint Committee on Cancer; 2010
15	Shimada K, Nakamura M, Ishida E and Konishi N: Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. Histol Histopathol. 21:415–422. 2006.PubMed/NCBI
16	Kunz M and Ibrahim SM: Molecular responses to hypoxia in tumor cells. Mol Cancer. 2:232003. View Article : Google Scholar : PubMed/NCBI
17	Semenza GL: Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
18	Mizobuchi H, García-Castellano JM, Philip S, Healey JH and Gorlick R: Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res. 466:2052–2059. 2008. View Article : Google Scholar : PubMed/NCBI
19	Kubo T, Piperdi S, Rosenblum J, et al: Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 112:2119–2129. 2008. View Article : Google Scholar : PubMed/NCBI
20	Zhou Q, Zhu Y, Deng Z, Long H, Zhang S and Chen X: VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 20:13–19. 2011. View Article : Google Scholar
21	Ko HS, Uehara T, Tsuruma K and Nomura Y: Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains. FEBS Lett. 566:110–114. 2004. View Article : Google Scholar : PubMed/NCBI
22	Kim TY, Kim E, Yoon SK and Yoon JB: Herp enhances ER-associated protein degradation by recruiting ubiquilins. Biochem Biophys Res Commun. 369:741–746. 2008. View Article : Google Scholar : PubMed/NCBI
23	Lim PJ, Danner R, Liang J, et al: Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD. J Cell Biol. 187:201–217. 2009. View Article : Google Scholar : PubMed/NCBI
24	N’Diaye EN, Kajihara KK, Hsieh I, et al: PLIC proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. EMBO Rep. 10:173–179. 2009. View Article : Google Scholar : PubMed/NCBI
25	Rothenberg C, Srinivasan D, Mah L, et al: Ubiquilin functions in autophagy and is degraded by chaperone-mediated autophagy. Hum Mol Genet. 19:3219–3232. 2010. View Article : Google Scholar : PubMed/NCBI
26	Skene JP and Cleveland DW: Hypoxia and Lou Gehrig. Nat Genet. 28:107–108. 2001. View Article : Google Scholar : PubMed/NCBI
27	Dhanasekaran DN and Reddy EP: JNK signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
28	Porras A, Zuluaga S, Black E, Valladares A, Alvarez AM, Ambrosino C, Benito M and Nebreda AR: p38α mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell. 15:922–933. 2004. View Article : Google Scholar :
29	Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U and Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509–4515. 1996.PubMed/NCBI
30	Vaupel P and Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 9(Suppl 5): S4–S9. 2004. View Article : Google Scholar
31	Björnsson J, Inwards CY, Wold LE, Sim FH and Taylor WF: Prognostic significance of spontaneous tumour necrosis in osteosarcoma. Virchows Archiv A Pathol Anat. 423:195–199. 1993. View Article : Google Scholar